美股市场个股详情
TVTX Travere Therapeutic
- 6.750
- +0.200+3.05%
收盘价 05/07 16:00 (美东)
- 6.750
- 0.0000.00%
盘后 16:20 (美东)
5.14亿总市值-3391市盈率TTM
7.690最高价6.740最低价193.81万股成交量7.400今开6.550昨收1367.47万成交额3.45%换手率亏损市盈率(静)7612.90万总股本19.54252周最高6.94市净率3.79亿流通值5.12052周最低--股息TTM5616.20万流通股37.040历史最高--股息率TTM14.50%振幅0.000历史最低7.055平均价1股每手
Travere Therapeutic股票讨论区
登录发表评论
$Travere Therapeutic(TVTX.US$ Travere Therapeutics Says Berger's Disease Treatment Granted EU Conditional Marketing Authorization
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...
MT Newswires· 43 mins Travere Therapeutics (TVTX) and CSL Vifor said Wednesday the European Commission granted conditional marketing authorization for Filspari as a treatment for adults with primary Immunoglobulin A Nephropathy, or Berger's disease.
CSL Vifor expects to launch sales of the drug in Europe beginning in H2. The authorizati...
1
8
$Travere Therapeutic(TVTX.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
$CG Oncology(CGON.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$美国联合医疗(UTHR.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Insmed(INSM.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$乌龙制药(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Jaguar Health(JAGX.US$ Phas...
19
The continuous decline in share price and revenue indicates unresolved challenges within the company. The company's future growth is uncertain and there are 4 warning signs in the investment analysis of Travere Therapeutics.
1
$Travere Therapeutic(TVTX.US$ Travere Therapeutics And CSL Vifor Announced That The European Medicines Agency's CHMP Has Recommended Approval Of Sparsentan For Primary IgA Nephropathy With A Urine Protein Excretion >1.0 G/Day; European Commission Decision Is Expected In Q2 2024
Travere Therapeutics' future revenue performance is expected to decline, contributing to its low P/S. Shareholders accept this as they anticipate no pleasant surprises in future revenue. A strong share price rise seems unlikely under these circumstances.
$Travere Therapeutic(TVTX.US$ Travere Therapeutics Has Opened Enrollment In HARMONY Phase 3 Trial Of Pegtibatinase For Classical Homocystinuria Compared To Placebo In Participants Who Are Receiving Standard Of Care![]()
$Travere Therapeutic(TVTX.US$ Never ceases to amaze me! A ticker actually get approval and falls? The a ticker gets a approval to just start and it goes 35%+! hehehe![]()
$Travere Therapeutic(TVTX.US$ Travere Therapeutics Says Pre-NDA Meeting With FDA for IgA Nephropathy Drug 'Successful'; Plans 20% Job Cut; Shares Jump Pre-Bell
MT Newswires· 2 mins ago![]()
MT Newswires· 2 mins ago
6
$Travere Therapeutic(TVTX.US$ Travere Plans To Submit SNDA To FDA In Q1 2024 For Conversion Of Existing US Accelerated Approval Of FILSPARI (Sparsentan) In IgAN To Full Approval![]()
3
暂无评论
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅
Stock_Drift : Slept in?
Trytosaveabit楼主 Stock_Drift: Power was from 3:11AM to 4:52AM hehehe
Stock_Drift Trytosaveabit楼主: Just messing around.
I have the same new (ish) day job but bumped up a position and it’s KILLING my day trading. I work 8-4 EST.
Oooooofffff!!!!
Trytosaveabit楼主 Stock_Drift: Yeah that gets in the way! Hehehe! Where I live in the mountains, power goes out fairly often! It’s getting better and doesn’t happen as often as it used to! Hehehe
Stock_Drift Trytosaveabit楼主: I’m Midwest, gotta have a generator on standby. It’s SOP.
查看更多评论...